✦ LIBER ✦

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

✍ Scribed by Josef S Smolen; Andre Beaulieu; Andrea Rubbert-Roth; Cesar Ramos-Remus; Josef Rovensky; Emma Alecock; Thasia Woodworth; Rieke Alten

Book ID: 117302691
Publisher: The Lancet
Year: 2008
Tongue: English
Weight: 197 KB
Volume: 371
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(08)60453-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of rheumatoid arthritis with h

Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial

✍ Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Sh 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 3 views

## Abstract ## Objective Interleukin‐6 (IL‐6) is a pleiotropic cytokine that regulates the immune response, inflammation, and hematopoiesis. Overproduction of IL‐6 plays pathologic roles in rheumatoid arthritis (RA), and the blockade of IL‐6 may be therapeutically effective for the disease. This s

Anti–interleukin-6 receptor antibody the

Anti–interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled study

✍ Rainer H. Straub; Peter Härle; Seizo Yamana; Takemasa Matsuda; Kiyoshi Takasugi; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 2 views

Double-blind randomized controlled clini

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

✍ R. N. Maini; P. C. Taylor; J. Szechinski; K. Pavelka; J. Bröll; G. Balint; P. Em 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 3 views

A double-blind, placebo-controlled study

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis

✍ Nancy J. Olsen; Raye H. Brooks; John J. Cush; Peter E. Lipsky; E. William St. Cl 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 654 KB

Objective. To evaluate the efficacy of an antLCD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA). Methods. A total of 104 evaluable patients were enrolled in a multicenter, double-blind, multiple-dose, placebo-controlled study of CDS-IC. Results. Treatment with CD

Efficacy and safety of tocilizumab in pa

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

✍ Shumpei Yokota; Tomoyuki Imagawa; Masaaki Mori; Takako Miyamae; Yukoh Aihara; Sh 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 225 KB

Therapeutic benefit of blocking interleu

Therapeutic benefit of blocking interleukin-6 activity with an anti–interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial

✍ E. H. S. Choy; D. A. Isenberg; T. Garrood; S. Farrow; Y. Ioannou; H. Bird; N. Ch 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB 👁 1 views